About: Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin
Creator	Sánchez, Carlos Katterine Bonilla-Aldana, D Mendoza, Luis Rodríguez-Morales, Alfonso Fernandez-Suarez, Hugo Millan, William Millán-Oñate, José
source	Medline; PMC
abstract	BACKGROUND: COVID-19 pandemics is a challenge for public health and infectious diseases clinicians, especially for the therapeutical approach that is not yet adequately defined. Amid this situation, investigational agents are being used, including chloroquine. We report here the clinical features and therapeutic course of the first reported patient with confirmed COVID-19 pneumonia that recovered in Colombia, after the use of chloroquine and clarithromycin. CASE PRESENTATION: A 34-year-old male, returning from Spain, presented with complaints of fever, and cough, and class-II obesity, being hospitalized. The respiratory viruses and bacteria tested by FilmArray(®) PCR were negative. Two days later, clarithromycin was started because the patient was suspected as community-acquired pneumonia. At the third day, the rRT-PCR confirmed the SARS-CoV-2 infection. A day later, chloroquine was started because of that. His chest computed tomography was performed and showed bilateral multifocal ground-glass opacities with consolidation, which suggested viral pneumonia as a differential diagnosis. Progressively his clinical condition improved and at day 9, patient rRT-PCR for SARS-CoV-2 became negative. The patient was discharged and isolated at home per 14 days. CONCLUSIONS: Our patient improved significantly. This and other COVID-19 cases are urgently demanding results from clinical trials that support evidence-based therapeutical approaches to this pandemic and the clinical management of patients, especially those at critical care.
has issue date	2020-04-24(xsd:dateTime)
bibo:doi	10.1186/s12941-020-00358-y
bibo:pmid	32331519
has license	cc-by
sha1sum (hex)	8899f57cc5d67322747ec85350bc3fdc650a8ed4
schema:url	https://doi.org/10.1186/s12941-020-00358-y
resource representing a document's title	Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin
has PubMed Central identifier	PMC7180682
has PubMed identifier	32331519
schema:publication	Ann Clin Microbiol Antimicrob
resource representing a document's body	covid:8899f57cc5d67322747ec85350bc3fdc650a8ed4#body_text
is schema:about of	named entity 'chloroquine' named entity 'APPROACH' named entity 'chloroquine' named entity 'COVID-19' named entity 'clinical features' named entity 'public health' named entity 'clarithromycin' named entity 'thrombocytopenia' named entity 'SARS-CoV' named entity 'leukopenia' named entity 'Mexico' named entity 'Italy' named entity 'clinical trials' named entity 'antiviral activity' named entity 'infection' named entity 'high affinity' named entity 'viral load' named entity 'cough' named entity 'hand washing' named entity 'COVID' named entity 'Toxoplasma gondii' named entity 'physical examination' named entity 'COVID' named entity 'serum' named entity 'SARS-CoV-2' named entity 'bacteria' named entity 'ACE2 receptor' named entity 'SARS-CoV-2' named entity 'H5N1' named entity 'SARS-CoV-2' named entity 'intravenous' named entity 'antiviral activity' named entity 'arbovirosis' named entity 'Spain' named entity 'pneumonia' named entity 'COVID' named entity 'anxiety' named entity 'control group' named entity 'SARS-CoV-2' named entity 'MERS-CoV' named entity 'hypoalbuminemia' named entity 'rRT-PCR' named entity 'hydroxychloroquine' named entity 'cough' named entity 'blood pressure' named entity 'WHO' named entity 'fatigue' named entity 'Italy' named entity 'azithromycin' named entity 'Valle del Cauca' named entity 'infection' named entity 'COVID' named entity 'QT prolongation' named entity 'therapeutical' named entity 'public health' named entity 'SARS-CoV-2' named entity 'intravenous' named entity 'self-medication' named entity 'computed tomography' named entity 'inhalation' named entity 'therapeutical' named entity 'SARS-CoV-2' named entity 'infection' named entity 'gram-positive' named entity 'respiratory rate' named entity 'fever' named entity 'emergency department' named entity 'Colombia' named entity 'Germany' named entity 'Influenza' named entity 'Valle del Cauca' named entity 'Buga' named entity 'fever' named entity 'Infectious Diseases' named entity 'Latin America'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software